KRAS and lung carcinoma: Oncology experienced a similar revolution about a decade ago, where instead of treating cancer in a single organ (e.g., lung cancer) as a single disease, treatment, and prognosis are now based on the genomic profile of the cancer cells (e.g., cancers with KRAS mutations and low PD-L1 expression).